Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Leases (2022 - 2025)

Axsome Therapeutics' Current Leases history spans 4 years, with the latest figure at $434000.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 76.35% year-over-year to $434000.0; the TTM value through Dec 2025 reached $434000.0, down 76.35%, while the annual FY2025 figure was $434000.0, 76.35% down from the prior year.
  • Current Leases for Q4 2025 was $434000.0 at Axsome Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.5 million in Q3 2025 and bottomed at $108000.0 in Q1 2023.
  • The 4-year median for Current Leases is $581560.0 (2022), against an average of $888452.8.
  • The largest annual shift saw Current Leases crashed 88.83% in 2023 before it soared 967.59% in 2024.
  • A 4-year view of Current Leases shows it stood at $425000.0 in 2022, then surged by 198.12% to $1.3 million in 2023, then skyrocketed by 44.83% to $1.8 million in 2024, then plummeted by 76.35% to $434000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Current Leases are $434000.0 (Q4 2025), $2.5 million (Q3 2025), and $337000.0 (Q2 2025).